Hemostemix and FireFly Neuroscience’s Brain Network Analytics (BNA™) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01 Read More
Investor Relations Hemostemix and CytoImmune Amend Manufacturing Agreement to Accelerate Global Scale-Up Read More
Hemostemix’ Second Round Interviews with Executive Vice President Business Development Candidates Read More
Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to its Scientific Advisory Board Read More
Hemostemix Announces Amendment of its $2.5 Million 5 Year Convertible Debenture Issued on June 11, 2021, Resulting in an Expected Interest Saving of Approximately $570,000 Read More
